NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines.

With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

Company Growth (employees)
Edinburgh, GB
Size (employees)
19 (est)
NuCana was founded in 2008 and is headquartered in Edinburgh, GB

Key People at NuCana

Hugh S. Griffith

Hugh S. Griffith

Co-Founder, CEO & Board Member
Ian Abercrombie

Ian Abercrombie

Business Unit Director
Chris Wood

Chris Wood

Executive Chairman & Medical Director

NuCana Office Locations

NuCana has an office in Edinburgh
Edinburgh, GB (HQ)
10 Lochside Place

NuCana Metrics

Summary Metrics

Founding Date


Total Funding

$67.5 m

Latest funding size

$57 m

Time since last funding

about 3 years


NuCana's latest funding round in April 2014 was reported to be $57 m. In total, NuCana has raised $67.5 m

NuCana Financial Metrics

Net income (FY, 2015)

(£5.3 m)

Cash (31-Dec-2015)

£29.2 m
FY, 2015

Pre tax profit

(£6.5 m)

Net Income

(£5.3 m)
FY, 2014FY, 2015


£36.4 m£29.2 m

Accounts Receivable

£639.5 k£148.8 k

Current Assets

£37.1 m£30.7 m


£11.6 k£14.5 k


£462.2 k£926.9 k

Total Assets

£37.5 m£31.7 m

Accounts Payable

£726.7 k£507.6 k

Current Liabilities

£726.7 k£1.7 m

Retained Earnings

(£5.3 m)

Total Equity

£36.8 m£30 m

Financial Leverage

1 x1.1 x
FY, 2015

Cash From Operating Activities

(£4.5 m)

Income Taxes Paid

£1.2 m
Y, 2015

Financial Leverage

1.1 x

NuCana Online Presence

NuCana Company Life

You may also be interested in